In recent studies, chemerin was also found to positively correlate with systemic inflammation biomakers (i.e. CRP, WBC count), insulin resistance, dyslipidemia and hepatic disorders in incident and maintenance HD patients34,35. This evidence concerns the gene RARRES2 and liver disorder.